Postprandial SMBG
Continuous glucose monitoring systems
Flash glucose monitoring systems
References
8 Does HbA1c Remain the Most Important Therapeutic Target in Outpatient Management of Diabetes?
The glucose hypothesis and vascular risk
Measuring glycemic control in the clinical management of diabetes
Additional therapeutic targets to consider for hyperglycemia in the outpatient management of diabetes
Summary
References
9 Technology Issues: Continuous Glucose Monitoring, Insulin Pumps, and Closed Loop Control for Patients with Diabetes
Introduction
Continuous Glucose Monitoring (CGM) for Diabetes Care
Currently Approved CLC for T1DM
Post‐marketing Studies
Ongoing Pivotal Studies/Anticipated Closed Loop System
Closed Loop Control Initiation at Onset of T1D
CLC is Being Tested in Specific Subgroups with Type 1 Diabetes at Present
Cost of Diabetes Technologies
Insulin Pump Use for People With T2DM
Conclusion
References
10 Optimizing Diet in Patients with Diabetes
Summary
References
11 Are Insulin Sensitizers Useful Additions to Insulin Therapy?
Insulin sensitizers
Biguanides
Thiazolidinediones
Discussion
References
12 Incretin‐Based Therapy for the Management of Type 2 Diabetes
Introduction
The incretin effect
Early development of GLP‐1 RA therapy
Clinical benefits and side effects of GLP‐1 RAs
The evidence for GLP‐1 ras in management of type 2 diabetes
The role of DPP‐4 inhibitors in type 2 diabetes management
Cardiovascular outcomes with incretin‐based therapies for type 2 diabetes
Incorporating incretin‐based therapy into clinical practice
Conclusions
Key points
References
8 PART III: Diagnosis and Management of Cardiovascular Risk Factors and Cardiovascular Disease 13 Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease Introduction Guidelines Hyperglycemia and risks of CVD Traditional risk factors Diabetes‐specific clinical risk predictors of CVD Nontraditional risk factors Screening tools Risk calculators Summary References 14 Choosing Medications for Type 2 Diabetes – What Weighting Should Be Given to Cardiovascular Risk Reduction? Diabetes and cardiovascular risk: how does it affect therapeutic goals? Metformin Sulfonylureas Thiazolidinediones Acarbose Colesevelam Pramlintide Bromocriptine Glucagon‐like peptide‐1‐based therapy SGLT‐2i Conclusions References 15 Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus Introduction: Prevalence and relationship of obesity and type 2 diabetes Therapeutic classes for the treatment of type 2 Diabetes and their effects on weight Use of diabetic medications for weight loss in patients without diabetes A Practical Guide to Choosing medication for type 2 diabetes
